Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
| Revenue (TTM) | $2.59B |
| Gross Profit (TTM) | $1.35B |
| EBITDA | $441.00M |
| Operating Margin | 11.20% |
| Return on Equity | 3.11% |
| Return on Assets | 1.66% |
| Revenue/Share (TTM) | $96.20 |
| Book Value | $268.30 |
| Price-to-Book | 1.41 |
| Price-to-Sales (TTM) | 3.94 |
| EV/Revenue | 3.79 |
| EV/EBITDA | 17.28 |
| Quarterly Earnings Growth (YoY) | 18.70% |
| Quarterly Revenue Growth (YoY) | -0.10% |
| Shares Outstanding | $21.68M |
| Float | $21.35M |
| % Insiders | 16.41% |
| % Institutions | 91.25% |
Volatility is currently contracting
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIO and any ticker you trade — then tracks every position and per-strategy win rate.
